Boehringer Ingelheim’s ifinatamab deruxtecan development hit a setback as the company voluntarily withdrew its biologics license application in previously treated extensive-stage small cell lung cancer. The withdrawal indicates the regulatory path for the antibody-drug conjugate is paused before a final FDA decision. For the sector, BLA withdrawal can quickly reshape competitive positioning in a space where ADCs are expected to deliver targeted efficacy with manageable safety. It also raises attention on what the agency may have flagged—typically tied to clinical data completeness, manufacturing, or benefit-risk assessment. The move will likely redirect resources to additional data generation and may affect partnered planning for next-generation ADC programs in SCLC.